Clik here to view.
Haberman Associates in Nature Biotechnology article on Bristol-Myers Squibb...
TweetLogo for illustration purposes only. I was quoted in an article entitled “Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall”, by freelance journalist Emma Dorey (Brighton, UK), in the...
View ArticleClik here to view.
ZymoGenetics CEO Doug Williams moves to Biogen Idec as R&D chief
TweetSource: Mnolf http://bit.ly/gEg5yo In our November 11, 2010 blog post, we discussed the September 2010 acquisition of Seattle biotech firm ZymoGenetics by Bristol-Myers Squibb (BMS). Also in...
View ArticleClik here to view.
The 2011 Nobel Prize in Physiology or Medicine–Innate and Adaptive Immunity
Tweet Blood cells Our November 25, 2011 article on this blog focused on Ralph Steinman, one of the three winners of The Nobel Prize in Physiology or Medicine for 2011. That article focused on...
View ArticleClik here to view.
Developing resistance-free antibiotics by targeting quorum sensing
Tweet Quorum sensing synthetic biology project http://bit.ly/LO1ynR Way back in May 2000, Decision Resources published my short report entitled “New approaches to small-molecule antibacterial drug...
View ArticleClik here to view.
Haberman Associates in “Pink Sheet” article on the cystic fibrosis drug market
Tweet Lumacaftor (Vertex’ VX-809) I was quoted in an article in the March 11, 2013 issue of Elsevier Business Intelligence’s The Pink Sheet by senior writer Joseph Haas. The article is entitled...
View ArticleClik here to view.
Chemokine receptors and the HIV-1 entry inhibitor maraviroc
TweetMaraviroc In April 2012, Informa’s Scrip Insights published our book-length report, “Advances in the Discovery of Protein-Protein Interaction Modulators.” We also published a brief introduction...
View Article
